Sinopharm Group Co Ltd
F:X2S1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sinopharm Group Co Ltd
F:X2S1
|
CN |
|
I
|
International Paper Co
F:INP
|
US |
|
A
|
Asia Capital Group PCL
SET:ACAP
|
TH |
|
B
|
BlackRock Inc
XMUN:BLQA
|
US |
|
B
|
Basf Se
XBER:BAS
|
DE |
|
N
|
NTT Data Corp
XBER:NT5
|
JP |
|
S
|
Swisscom AG
XBER:SWJ
|
CH |
|
Fairvest Ltd
F:2T20
|
ZA |
|
K
|
Kering SA
XMUN:PPX
|
FR |
|
A
|
Albemarle Corp
F:AMC
|
US |
|
Aviva PLC
LSE:AV
|
UK |
|
O
|
Old Dominion Freight Line Inc
XBER:ODF
|
US |
|
A
|
Aflac Inc
LSE:0H68
|
US |
|
G
|
Gran Tierra Energy Inc
AMEX:GTE
|
CA |
|
I
|
International Business Machines Corp
XMUN:IBM
|
US |
|
Sekisui Chemical Co Ltd
TSE:4204
|
JP |
Wall St Price Targets
X2S1 Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for X2S1 is 12.87 EUR with a low forecast of 10.36 EUR and a high forecast of 15.7 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S1's stock price target?
Price Target
12.87
EUR
According to Wall Street analysts, the average 1-year price target for X2S1 is 12.87 EUR with a low forecast of 10.36 EUR and a high forecast of 15.7 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 6%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.
